Capitulo1
Capitulo2
Capitulo3
Capitulo4
Capitulo5
Capitulo6
Capitulo7
Capitulo8
Capitulo2
Capitulo3
Capitulo11
Capitulo12
Capitulo13
Capitulo14
Capitulo15
Capitulo16
Capitulo17


1. American Diabetes Association,American Academy of Neurology: Consensus statement: report and recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes Care 1988, 11:592–597.

2. Vinik Al, Mitchell BD, Leichter SB, et al.: Epidemiology of the complications of diabetes. In Diabetes: Clinical Science and Practice, Edited by Leslie RDG, Robbins DC. Cambridge: Cambridge University Press; 1995:15,221.

3. Kjiturnan M,Welborn T, McCann V, et al.: Prevalence of diabetic complications in relation to risk factors. Diabetes 1986, 35:1332–1339.

4. Young MJ, Boulton AJ, MacLeod AF, et al.: A multicenter study of the prevalence of diabetic neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993, 36:150–154.

5. Feldman JN, Hirsch SR, Bever BS, et al.: Prevalence of diabetic nephropathy at time of treatment for diabetic retinopathy. In Diabetic Renal-Retinal Syndrome. Edited by Friedman L’Esperance FA. London: Grune & Stratton; 1982:9.

6. Dyck PJ, Kratz KM, Karnes MS, et al.: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993, 43:817–824.

7. Brownlee M:Advanced products of nonenzymatic glycosylation and the pathogenesis of diabetic complications. In Diabetes Mellitus.Theory and Practice. Edited by Rifkin H, Porte D. New York: Elsevier, 1990:279.

8. Diabetes Control and Complications Trial Research Group: Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 1995, 38:869–880.

9. Vinik Al, Newlon PG, Lauterio TJ, et al.: Nerve survival and regeneration in diabetes. Diabetes Rev 1995, 3:139–157.

10. Said G, Goulon-Gorcau C, Lacroix C, Moulonguet A: Nerve biopsy findings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994, 35:559–569.

11. Krendel DA, Costigan DA, Hopkins LC: Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995, 52:1053–1061.

12. Vinik AI, Milicevic Z, Colen LB, et al.: Histopathological and electrophy-siologic heterogeneity in patients with proximal diabetic neuropathy (PDN) [abstract]. Diabetes 1996, 769:209.

13. Malik RA,Tesfaye S.Thompson SD, et al.: Transperineurial capillary abnor-malities in the sural nerve of patients with diabetic neuropathy. Microvasc Res 1994, 48:236–245.

14. Dyck P, Hansen S, Karnes J: Capillary number and percentage closed in human diabetic sural nerve. Proc Natl Acad Sci USA 1985, 82:2513–2517.

15. Low PA, Lagerlund TD, McManis PG: Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy. Int Rev Neurobiol 1989, 31:355–438.

16. Yasuda H, Dyck P:Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. New Urology 1987, 37:20–28.

17. Malik RA,Veves A, Masson EA, et al.: Endoneurial capillary abnormalities in human diabetic neuropathy. J Neurol Neurosurg Psychiatry 1992, 55:557–561.

18. Tuck RR, Schinelzer JD, Low PA: Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 1984, 107:935–950.

19. Newrick PG,Wilson AJ, Jakubowski J, et al.: Sural nerve oxygen tension in diabetes. Br Med J 1986, 293:1053–1054.

20. Zachodne DW, Ho LT: Normal blood flow but lower oxygen tension in diabetes of young rats: microenvironment and the influence of sympa-thectomy. Can J Physiol Pharmacol 1992, 70:651–659.

21. Hotta N, Koh N, Sakakibara F, et al.: Effect of proplionyl-L-carnitine on motor nerve conduction, autonomic cardiac function, and nerve blood flow in rats with streptozotocin-induced diabetes: comparison with an aldose reductase inhibitor. Diabetes 1992, 41:587–591.

22. Vinik Al, Holland MT, LeBeau JM, et al.: Diabetic neuropathies. Diabetes Care 1992, 15:1926–1975.

23. Dawson DM: Entrapment neuropathies of the upper extremities. N Engl J Med 1993, 329:2013–2018.

24. Leedman PJ, Davis S, Harrison LS: Diabetic amyotrophy-reassessment of the clinical spectrum. Aust N Z J Med 1988, 18:768–773.

25. Barohn RJ, Salienk Z,Warmolts JR, Mendell JR:The Bruns Garland syndrome (diabetic amyotrophy). Arch Neurol 1991, 48:1130–1135.

26. Chia L, Fernandez A, Lacroix C: Contribution of nerve biopsy findings to the diagnosis of disabling neuropathy in the elderly: a retrospective review of 100 consecutive patients. Brain 1996, 119:1091–1098.

27. Hanson PH, Schumaker P, Debugne T, Clerin M: Evaluation of somatic and autonomic small fibers neuropathy in diabetes. Am J Phys Med Rehabil 1992, 71:44–47.

28. Dyck PJ: Small-fiber neuropathy determination. Muscle Nerve 1988, 11:998–999.

29. Jarnal GA, Hansen S,Weir Al, Ballantyne JP:The neurophysiologic investigation of small fiber neuropathies. Muscle Nerve 1987, 10:537–545.

30. Shapiro SA, Stansberry KB, Hill MA, et al. : Normal blood flow response and vasomotion in the diabetic Charcot foot. J Diabetes Complications 1998, 12:147–153.

31. Burnstock G, Ralevic V: New insights into the local regulation of blood flow by perivascular nerves and endothelium. Br J Plastic Surg 1994, 47:527–543.

32. Stansberry KB, Hill MA, Shapiro SA, et al.: Impairment of peripheral blood flow responses in diabetes resembles an enhanced aging effect. Diabetes Care 1997, 20:1711–1716.

33. Ewing J, Campbell IW, Clarke BF, et al.: Heart rate changes in diabetes mellitus. Lancet 1981, 1:183–186.

34. Kahn J, Ida B,Vinik A: Stress and cardiovascular function in diabetes. Diabetes Care 1985, 12:3–5.

 voltar